{
    "clinical_study": {
        "@rank": "68620", 
        "arm_group": [
            {
                "arm_group_label": "Metformin group", 
                "arm_group_type": "Experimental", 
                "description": "Metformin 500mg 1 tablet p.o. bid"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 tablet p.o. bid"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is the evaluation of effect of metformin on obesity and metabolic\n      disturbance in patients taking clozapine."
        }, 
        "brief_title": "The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study, the investigators are going to examine the effect of metformin on obesity and\n      metabolic disturbance in patients with schizophrenia who have taken clozapine.The metformin\n      500mg will be administrated per oral twice a day for 24 weeks and for control group, placebo\n      will be given same route and process."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 ~ 65\n\n          -  Patient with schizophrenia according to DSM-IV criteria\n\n          -  Patient have signed on the informed consent, and well understood the objective and\n             procedure of this study.\n\n          -  Patient taking clozapine 3months or more\n\n          -  Patient increased in weight more than 10 % of that of before antipsychotics use\n\n        Exclusion Criteria:\n\n          -  Patient taking other antipsychotics with clozapine\n\n          -  Patient in treatment of diabetes\n\n          -  Patient in treatment of dyslipidemia\n\n          -  Allergy or hypersensitivity to metformin\n\n          -  Pregnant or breast-feeding female patient.\n\n          -  Patient with severe medical condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654640", 
            "org_study_id": "DW_Metformin"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin group", 
                "description": "metformin 500mg p.o. bid for 24 weeks", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Diabex"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "placebo 1T bid", 
                "intervention_name": "Placebo (for metformin)", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clozapine", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "schizophrenia", 
            "obesity", 
            "clozapine", 
            "metformin"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "link": {
            "description": "study site", 
            "url": "http://www.snuh.org/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "hjlee.np@gmail.com", 
                    "last_name": "Hyun Jeong Lee, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Yong Min Ahn, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Hyun Jeong Lee, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Yong Min Ahn, MD., PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine", 
        "overall_contact": {
            "email": "hjlee.np@gmail.com", 
            "last_name": "Hyun Jeong Lee, MD"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Yong Min Ahn, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "change of weight after 12-week, 24-week. calculation; (weight of 12-week - weight of baseline)/baseline weight (weight of 24-week - weight of baseline)/baseline weight", 
            "measure": "change of weight", 
            "safety_issue": "No", 
            "time_frame": "baseline, 12 weeks, 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654640"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Yong Min Ahn", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "Positive and Negative Symptom Scale(PANSS)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "MADRS(montgomery asberg depression rating scale)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "Clinical Global Impression-severity(CGI-S)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "Clinical Global Impression-improvement(CGI-I)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "Beck's Depression Inventory(BDI)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "Liverpool University Neuroleptic Side Effect Rating Scale(LUNSERS)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "World Health Organization Quality of Life-BREF (WHOQOL-BREF)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 1-week, 4-week, 12-week, 24-week(end-point)", 
                "measure": "Short form(36) Health survey (SF-36)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "baseline, 12-week, 24-week", 
                "measure": "abdominal fat amount CT", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }, 
            {
                "description": "waist circumference, blood pressure cholesterol,triglyceride, HDL-cholesterol,fasting glucose", 
                "measure": "change of prevalence of metabolic syndrome", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks, 24 weeks"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Daewoong Pharmaceutical Co. LTD.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}